Nucleic Acid Therapeutic Delivery System Development for PC

Nucleic Acid Therapeutic Delivery System Development for PC

Nucleic Acid Therapeutic Delivery System Development for PC

The goal of nucleic acid therapy is to provide a safe and effective treatment for cancer patients by specifically targeting and suppressing cancer cells in the body. Nucleic acid therapy has great potential in the treatment of pancreatic cancer (PC), either by turning on genes that induce apoptosis or by turning off genes that promote tumor cell proliferation. Alfa Cytology has launched a powerful PC nucleic acid therapeutic delivery system platform that can produce, modify and characterize a range of delivery systems with desirable characteristics, including viral vectors, lipid nanoparticles (LNPs), and exosomes.

Why need PC nucleic acid therapeutic delivery system

PC constitutes one of the deadliest types of cancers and has a very poor prognosis. In addition to cancer cells, the tumor microenvironment, formed by resident and recruited cells and extracellular matrix, also contributes to the acquisition of PC characteristics. Therefore, PC involves a high heterogeneity, inefficient drug penetration, and desmoplastic tumor microenvironment. The major limitation of nucleic acid drugs is their delivery to the target tissue and cells, as well as in tuning their expression in cancer cells. With advances in the production and modification of nucleic acid therapeutic delivery systems, the application of nucleic acid drugs for PC treatment has been greatly facilitated.

The service offering at Alfa Cytology

Nucleic Acid Therapeutic Delivery System Development for PC

An efficient delivery system must ensure that nucleic acid reaches its sites of action and avoid its degradation by the nucleases present in the biological fluids. Our team of experts has years of extensive experience in developing nucleic acid therapeutic delivery systems. We are dedicated to offering a series of optimal PC nucleic acid therapeutic delivery vehicles, including viral vectors, LNPs, and exosomes. Our services include customized design, flexible production, and careful optimization and characterization of the nucleic acid therapeutic delivery systems, aiming to help customers facilitate the development and application of nucleic acid drugs for PC.

  • Development of viral vectors for nucleic acid drugs

Viral vectors are the first delivery systems developed and most extensively studied nucleic acid delivery platform technology. Viral vectors have two major advantages, including efficiently delivering RNAs in vivo and allowing stable gene silencing. We specialize in a number of commonly used viral nanoparticles, including adeno-associated virus (AAV) vectors, adenoviral vectors, and lentiviral vectors. We are dedicated to providing powerful image datasets, quantitative data, and conclusions from the analysis to fully assist viral vector characterization.

  • Development of LNPs for nucleic acid drugs

As the most commonly used material for non-viral nucleic acid drug delivery, LNPs can not only protect nucleic acid against enzymatic degradation conditions but also allow nucleic acid to alter its biodistribution, cellular targeting, and cellular uptake mechanism. Our delivery platform can offer LNPs with high encapsulation efficiency and greater payload capacity. Our services have a fast turnaround time, low cost, and ensure the most effective LNP to support intracellular nucleic acid delivery in PC.

  • Development of exosomes for nucleic acid drugs

Exosomes hold promise as another drug delivery system to address the barriers to nucleic acid drug delivery. Exosomes are a class of extracellular vesicles composed of lipid bilayers with a diameter of 40 to 150 nm. Molecular analysis shows that the metastatic destination of cancer is determined by exosomes from cancer cells. And their organ specificity is determined by the integrins contained. By exploiting this intrinsic property, exosomes can be used to deliver nucleic acid drugs to targeted cancer cells. To obtain high-quality, functional exosomes for nucleic acid drug delivery, we can offer scalable exosome production and isolation services, as well as efficient exosome purification and characterization services.

For more about our services, please contact us. We are glad to work with you!


  1. Aghamiri, Shahin, et al. "Nonviral siRNA delivery systems for pancreatic cancer therapy." Biotechnology and Bioengineering 118.10 (2021): 3669-3690.
  2. Yamada, Yoji. "Nucleic Acid Drugs—Current Status, Issues, and Expectations for Exosomes." Cancers 13.19 (2021): 5002.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.